CliffBio
biologic

Retavase

reteplase

Loss of exclusivityOctober 2008projected — 12-year biologic exclusivity estimate
CompanyChiesi Usa, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameRetavase
Active ingredientreteplase
Strength10UNITS
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalOctober 1996
Marketing statusRx

More from Chiesi Usa, Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Retavase patent cliff — loss of exclusivity October 2008 | CliffBio